401 related articles for article (PubMed ID: 30887050)
1. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
Wong F; Boyer TD; Sanyal AJ; Pappas SC; Escalante S; Jamil K
Nephrol Dial Transplant; 2020 Sep; 35(9):1554-1561. PubMed ID: 30887050
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
4. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
Solé C; Solà E; Huelin P; Carol M; Moreira R; Cereijo U; Mas JM; Graupera I; Pose E; Napoleone L; dePrada G; Juanola A; Fabrellas N; Torres F; Morales-Ruiz M; Farrés J; Jiménez W; Ginès P
Liver Int; 2019 Jul; 39(7):1246-1255. PubMed ID: 30597709
[TBL] [Abstract][Full Text] [Related]
5. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
Erstad BL
Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
[TBL] [Abstract][Full Text] [Related]
6. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
Olson JC; Subramanian RM
PLoS One; 2024; 19(1):e0296690. PubMed ID: 38285703
[TBL] [Abstract][Full Text] [Related]
9. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
Arora V; Maiwall R; Rajan V; Jindal A; Muralikrishna Shasthry S; Kumar G; Jain P; Sarin SK
Hepatology; 2020 Feb; 71(2):600-610. PubMed ID: 30076614
[TBL] [Abstract][Full Text] [Related]
11. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
Sanyal AJ; Boyer T; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Blei A; Gülberg V; Sigal S; Teuber P;
Gastroenterology; 2008 May; 134(5):1360-8. PubMed ID: 18471513
[TBL] [Abstract][Full Text] [Related]
12. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin for hepatorenal syndrome.
Wong F
Curr Opin Gastroenterol; 2024 May; 40(3):156-163. PubMed ID: 38353275
[TBL] [Abstract][Full Text] [Related]
14. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C; Platzer S; Franken P; Aschenbach R; Wienke A; Schuhmacher U; Teichgräber U; Stallmach A; Steighardt J; Zipprich A;
Trials; 2023 Apr; 24(1):258. PubMed ID: 37020315
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.
Belcher JM; Parada XV; Simonetto DA; Juncos LA; Karakala N; Wadei HM; Sharma P; Regner KR; Nadim MK; Garcia-Tsao G; Velez JCQ; Parikh SM; Chung RT; Allegretti AS;
Am J Kidney Dis; 2022 May; 79(5):737-745. PubMed ID: 34606933
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
[TBL] [Abstract][Full Text] [Related]
19. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
